Preclinical and Clinical Evaluation of Novel Agents for Noninvasive Imaging of Prostate Cancer
Abstract
Imaging procedures play an important role in the current management of patients with prostate cancer. Despite advances in many of these methodologies, improvements are still needed, especially in the area of Nuclear Medicine. The radioiodinated phospholipid ether analogs being investigated under this grant represent a new class of radiopharmaceutical, which has provided excellent images of prostate tumors in animal models. Two of the newer analogs, namely NM-404 and NM-412, were found to be significantly superior to the prototype agent, NM-324 in both the rat and mouse tumor models, while avoiding the high first pass clearance by the liver displayed by NM-324. We are actively pursuing FDA approval of an ND to initiate pharmacokinetic, distribution and elimination studies of radioiodinated NM-404 in prostate cancer patients.
Document Details
- Document Type
- Technical Report
- Publication Date
- Feb 01, 2001
- Accession Number
- ADA397341
Entities
People
- Milton Gross
- Raymond Counsell
Organizations
- University of Michigan